Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and in-house competences also in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide (a once-daily prandial GLP-1 agonist) is marketed globally (ex-US) by Sanofi as Lyxumia® for the treatment of Type 2 diabetes. Sanofi also has the product in Phase III development as a single-injection combination with Lantus® (LixiLan) under a global license agreement. US regulatory filing of Lyxumia® is planned for summer 2015 and of LixiLan as early as end 2015.
Zealand proprietary pipeline includes danegaptide (prevention of ischemic reperfusion injury) and ZP4207 (a stable glucagon product to treat severe hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.
Year of foundation: 1998
No. of full time employees (end 2013): 91
Follow us on Twitter: @ZealandPharma